Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials -

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Information type: Randomised controlled trials
Source: The Lancet Respiratory Medicine
Specialities:
Summary
Tralokinumab, an anti-interleukin-13 human monoclonal antibody, did not reduce annualised asthma exacerbation rate (AAER) in participants with severe asthma in either STRATOS 1 (n=1207) nor STRATOS 2 (n=856).
UKMi comment
Tralokinumab via sub-cutaneous injection is being investigated for moderate-to-severe atopic dermatitis in patients who are candidates for systemic therapy.
Related links: